p55γ Targeting to Prevent Aortic Dissection via VSMC Phenotype Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for aortic dissection (AD) lack effective drugs and surgical interventions are costly and risky, necessitating a new therapeutic target for prevention and treatment.
Innovation Solution
Utilizing p55γ as a target for drug development, either through p55γ gene or protein activators, to regulate vascular smooth muscle cell (VSMC) phenotypic switching, maintaining a contractile phenotype and inhibiting AD formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical intervention is used to treat AD, then treatment effectiveness is improved, but treatment complexity and cost increase, and mortality rate increases
Solution Approach 1:
The patent replaces mechanical surgical intervention with a biochemical system. Specifically, it uses small molecule drugs or biologics that target the p55γ receptor to modulate VSMC phenotypic switching and inhibit elastic fiber degradation, thereby treating AD through molecular mechanisms rather than mechanical surgery.
Solution Approach 2:
The patent introduces p55γ as a molecular intermediary target. By developing drugs that activate or modulate p55γ signaling, the treatment mediates the therapeutic effect between the administered drug and the pathological process of AD, avoiding direct surgical intervention while achieving disease modification.
2Reliability
If surgical intervention is used to treat AD, then treatment effectiveness is improved, but mortality rate increases
Solution Approach 1:
The patent replaces high-risk mechanical surgery with low-risk biochemical therapy. By using p55γ-targeted drugs to inhibit elastic fiber degradation and prevent dissection propagation, the treatment achieves therapeutic effects without the procedural risks and mortality associated with surgical intervention.
3Adaptability or versatility
If no effective drug is used, then current treatment options are limited, but disease progression and mortality increase
Solution Approach 1:
The patent changes the therapeutic parameter from mechanical intervention to biochemical modulation. By targeting the p55γ receptor and its downstream signaling pathways (PI3K-AKT-mTOR), the treatment modifies the molecular parameters governing VSMC phenotypic switching and elastic fiber integrity, thereby preventing disease progression.
4Adaptability or versatility
If p55γ is used as a therapeutic target, then new treatment approach is provided, but mechanism complexity increases
Solution Approach 1:
The patent extracts and isolates the p55γ receptor as a specific therapeutic target from the complex network of signaling pathways. By focusing drug development on this single receptor and its immediate downstream effects on VSMC phenotype and elastic fiber metabolism, the treatment simplifies the therapeutic approach while addressing the underlying molecular mechanisms of AD.
Data Source
AI summary
Use of p55γ as a therapeutic target for aortic dissection (AD) is provided, belonging to the technical field of biomedicine. Over-expression of the p55γ inhibits formation of the AD and degradation of elastic fibers in mice induced by β-aminopropionitrile fumarate (BAPN); whereas knockdown of the p55γ in vascular smooth muscle cells (VSMCs) promotes the formation of the AD and the degradation of the elastic fibers induced by the BAPN. Mechanistically, the p55γ plays a role by maintaining phenotypic switching of the VSMCs, and knocking down the p55γ promotes phenotypic switching of the VSMCs from a contractile phenotype to a synthetic phenotype. The p55γ is used as a target in screening a drug for prevention and/or treatment of AD, such that a selected drug can effectively prevent and/or treat the AD, thus providing a new target for treating the AD.